Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Mar;54(3):207–212. doi: 10.1136/thx.54.3.207

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

J A van Noord 1, A Schreurs 1, S Mol 1, P Mulder 1
PMCID: PMC1745431  PMID: 10325895

Abstract

BACKGROUND—The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids.
METHODS—After a four week run in period of treatment with fluticasone propionate (100 µg twice daily if pre-trial dose was 400-600 µg inhaled corticosteroids or 250 µg twice daily if pre-trial dose was 800-1200 µg inhaled corticosteroids), 274 patients were randomised to treatment for 12 weeks with either salmeterol 50 µg twice daily plus the run in dose of fluticasone propionate or twice the run in dose of fluticasone propionate (200 or 500 µg twice daily). Outcome measures were daily records of peak expiratory flow (PEF), symptom scores, and clinic lung function.
RESULTS—The improvements in both the morning and evening PEF were better in the salmeterol than in the fluticasone propionate group, the mean increase in morning PEF being 19 l/min higher (95% CI 11.0 to 26.1) and in evening PEF being 16 l/min (95% CI 18.4 to 24.0) higher in the salmeterol group. The increase in forced expiratory volume in one second (FEV1) was 0.09 l greater in the salmeterol group than in the fluticasone propionate group after four weeks of treatment (95% CI 0.01 to 0.18), but not after 12 weeks. Both regimens showed an increase in symptom free days and a reduction in the need for rescue salbutamol both during the day and the night, but these improvements were greater in the salmeterol group. There were no significant differences between the groups in adverse effects or in the number of rescue courses of oral corticosteroids.
CONCLUSIONS—In this group of patients still symptomatic despite 100 or 250 µg fluticasone propionate twice daily, the addition of salmeterol caused a greater improvement in lung function and symptom control than doubling the dose of fluticasone propionate.



Full Text

The Full Text of this article is available as a PDF (128.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhagat R., Kalra S., Swystun V. A., Cockcroft D. W. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest. 1995 Nov;108(5):1235–1239. doi: 10.1378/chest.108.5.1235. [DOI] [PubMed] [Google Scholar]
  2. Booth H., Bish R., Walters J., Whitehead F., Walters E. H. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax. 1996 Nov;51(11):1100–1104. doi: 10.1136/thx.51.11.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Britton M. G., Earnshaw J. S., Palmer J. B. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. Eur Respir J. 1992 Oct;5(9):1062–1067. [PubMed] [Google Scholar]
  4. Cheung D., Timmers M. C., Zwinderman A. H., Bel E. H., Dijkman J. H., Sterk P. J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203. doi: 10.1056/NEJM199210223271703. [DOI] [PubMed] [Google Scholar]
  5. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  6. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Reinikainen K., Selroos O. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392. doi: 10.1056/NEJM199108083250603. [DOI] [PubMed] [Google Scholar]
  7. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  8. Kalra S., Swystun V. A., Bhagat R., Cockcroft D. W. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest. 1996 Apr;109(4):953–956. doi: 10.1378/chest.109.4.953. [DOI] [PubMed] [Google Scholar]
  9. Newnham D. M., Grove A., McDevitt D. G., Lipworth B. J. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax. 1995 May;50(5):497–504. doi: 10.1136/thx.50.5.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  11. Pearlman D. S., Chervinsky P., LaForce C., Seltzer J. M., Southern D. L., Kemp J. P., Dockhorn R. J., Grossman J., Liddle R. F., Yancey S. W. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420–1425. doi: 10.1056/NEJM199211123272004. [DOI] [PubMed] [Google Scholar]
  12. Ramage L., Lipworth B. J., Ingram C. G., Cree I. A., Dhillon D. P. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994 May;88(5):363–368. doi: 10.1016/0954-6111(94)90042-6. [DOI] [PubMed] [Google Scholar]
  13. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  14. Ullman A., Hedner J., Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis. 1990 Sep;142(3):571–575. doi: 10.1164/ajrccm/142.3.571. [DOI] [PubMed] [Google Scholar]
  15. Verberne A. A., Frost C., Roorda R. J., van der Laag H., Kerrebijn K. F. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):688–695. doi: 10.1164/ajrccm.156.3.9611067. [DOI] [PubMed] [Google Scholar]
  16. Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]
  17. Yates D. H., Kharitonov S. A., Barnes P. J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1603–1607. doi: 10.1164/ajrccm.154.6.8970342. [DOI] [PubMed] [Google Scholar]
  18. Yates D. H., Sussman H. S., Shaw M. J., Barnes P. J., Chung K. F. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1170–1174. doi: 10.1164/ajrccm.152.4.7551366. [DOI] [PubMed] [Google Scholar]
  19. van Essen-Zandvliet E. E., Hughes M. D., Waalkens H. J., Duiverman E. J., Pocock S. J., Kerrebijn K. F. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis. 1992 Sep;146(3):547–554. doi: 10.1164/ajrccm/146.3.547. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES